Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Acquisitions (2017)

Viridian Therapeutics, Inc.\DE (VRDN) has 1 years of Acquisitions data on record, last reported at $1.3 million in Q1 2017.

  • For Q1 2017, Acquisitions changed N/A year-over-year to $1.3 million; the TTM value through Dec 2017 reached $1.3 million, changed N/A, while the annual FY2020 figure was $29.4 million, N/A changed from the prior year.
  • Acquisitions reached $1.3 million in Q1 2017 per VRDN's latest filing.
  • Across five years, Acquisitions topped out at $1.3 million in Q1 2017 and bottomed at $1.3 million in Q1 2017.